NCT00520637View on ClinicalTrials.gov

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2007

Conditions
Advanced Solid TumorsLymphoma
Interventions
DRUG

EZN-2208

Trial Locations (2)

77030

MD Anderson Cancer Center, Houston

60611-2927

Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, Chicago

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY